Rep. Thomas H. Kean, Jr. Sells Stryker Co. (NYSE:SYK) Stock

Representative Thomas H. Kean, Jr. (R-New Jersey) recently sold shares of Stryker Co. (NYSE:SYK). In a filing disclosed on March 14th, the Representative disclosed that they had sold between $15,001 and $50,000 in Stryker stock on February 26th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Sold $1,001 – $15,000 in shares of Magnera (NYSE:MAGN) on 2/12/2025.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 1/16/2025.
• Purchased $1,001 – $15,000 in shares of Crown (NYSE:CCK) on 1/7/2025.
• Purchased $1,001 – $15,000 in shares of Canadian Pacific Kansas City (NYSE:CP) on 12/27/2024.
• Purchased $1,001 – $15,000 in shares of Pernod Ricard (OTC:PRNDY) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 12/19/2024.
• Sold $1,001 – $15,000 in shares of Franklin Resources (NYSE:BEN) on 12/16/2024.
• Purchased $1,001 – $15,000 in shares of Prologis (NYSE:PLD) on 12/16/2024.

Stryker Stock Performance

SYK opened at $369.96 on Friday. The business’s fifty day moving average is $383.04 and its 200-day moving average is $373.37. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The firm has a market cap of $141.17 billion, a P/E ratio of 47.68, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the company earned $3.46 EPS. Sell-side analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is 43.30%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SYK. Needham & Company LLC reaffirmed a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Wednesday, January 29th. Argus set a $450.00 price target on shares of Stryker in a research report on Monday, February 3rd. Citigroup restated a “buy” rating and issued a $450.00 target price on shares of Stryker in a report on Wednesday, February 26th. Royal Bank of Canada increased their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Finally, Truist Financial increased their price target on shares of Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Hedge Funds Weigh In On Stryker

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assetmark Inc. lifted its position in Stryker by 30.7% during the third quarter. Assetmark Inc. now owns 1,013 shares of the medical technology company’s stock valued at $366,000 after purchasing an additional 238 shares during the last quarter. Harbour Investments Inc. lifted its holdings in shares of Stryker by 4.2% during the 3rd quarter. Harbour Investments Inc. now owns 6,330 shares of the medical technology company’s stock worth $2,287,000 after acquiring an additional 256 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Stryker in the third quarter worth $362,000. Aigen Investment Management LP bought a new position in Stryker in the third quarter valued at $493,000. Finally, Victory Capital Management Inc. lifted its stake in Stryker by 5.6% during the third quarter. Victory Capital Management Inc. now owns 163,822 shares of the medical technology company’s stock worth $59,182,000 after purchasing an additional 8,745 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.